Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025)
Innate Pharma (IPHA) posted quarterly Return on Capital Employed of 382.44% for Q4 2025, down 29132.0% year-on-year from N/an in Q4 2024, and down 142.2% on a QoQ basis from 157.9% in Q2 2025.
Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported Return on Capital Employed for 5 consecutive years, with 382.44% the latest figure, recorded in Q4 2025.
- Quarterly Return on Capital Employed fell 29132.0% year-over-year to 382.44% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 382.44% (down 29132.0% YoY) and the FY2025 annual result came in at 107.5%, down 6067.0% from the prior year.
- Return on Capital Employed eased to 382.44% in Q4 2025 per IPHA's latest filing, from 157.9% in the prior quarter.
- Over the last five years, Return on Capital Employed for IPHA reached as high as 27.48% in Q2 2021 and fell as low as 382.44% in Q4 2025.
- A 5-year average of 100.4% and a median of 50.22% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 1378 bps — and 2025, when it sank 29132 bps.
- Year by year, Return on Capital Employed stood at 47.7% in 2021, then fell by 3 bps to 49.0% in 2022, then dropped by 2 bps to 50.22% in 2023, then tumbled by 81 bps to 91.11% in 2024, then slumped by 320 bps to 382.44% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 382.44%, 157.9%, and 91.11% for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | -382.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -382.44% |
| Jun 30, 2025 | -157.90% |
| Dec 31, 2024 | -91.11% |
| Jun 30, 2024 | -42.00% |
| Dec 31, 2023 | -50.22% |
| Jun 30, 2023 | -55.78% |
| Dec 31, 2022 | -49.00% |
| Dec 31, 2021 | -47.70% |
| Jun 30, 2021 | -27.48% |